

Fibroblast Growth Factor Receptors available from Daresbury Proteins

Fibroblast Growth Factor Receptors (FGFRs) are a family of FGF-binding transmembrane receptors involved in the regulation of cell growth and proliferation, angiogenesis, and numerous developmental processes. They are highly conserved, consisting of three extracellular immunoglobulin-type domains, IgI, IgII and IgIII which enable ligand binding, a transmembrane domain, and an intracellular tyrosine kinase domain which exerts its downstream signalling effects. The signalling pathway activated by FGFR/FGF has been implicated in a number of cancers; consequently, FGFR inhibitors are being investigated as potential therapeutic agents in a number of cancer studies (1,2).


The different FGFR isoforms generated from alternative splicing of the FGFR genes display tissue-specific expression and varied FGF binding properties. Daresbury Proteins, using their novel stable mammalian expression system have generated high purity and low endotoxin, recombinant Human Fibroblast Growth Factor Receptors covering all the major splice variants.

Authentic mammalian proteins for high-end applications, recombinant FGFR1b and FGFR1c


Available from Daresbury Proteins, splice variant FGFR1b is an isoform representing an epithelial variant of FGFR1, while FGFR1c is a mesenchymal variant of FGFR1. Daresbury Proteins produces its Fibroblast Growth Factor Receptors with a C-terminal 10 x Histidine tag for ease of detection. This smaller tag has distinct functional advantages over the use of the Fc-tag found on similar products.

A focus on quality, recombinant FGFR2b and FGFR2c

FGFR2b is an alternatively spliced isoform representing an epithelial variant of FGFR2 while FGFR2c is a mesenchymal variant of FGFR2. These high-quality proteins have numerous laboratory applications; as part of an antibody validation process, FGFR2b and FGFR2c were used to validate commercial antibodies produced by Cambridge Research Biochemicals.



FGFR1c - Grade & Purity: >95% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).



Validation:

Western blot analysis of conditioned media from non-transfected HEK293 cells, FGFR2b-His and FGFR2c-His transfected HEK293 cells.

Lane 1: Conditioned media from non-transfected HEK293 cells

Lane 2: Conditioned media from HEK293 cells stably expressing soluble FGFR2b-His

Lane 3-4: Conditioned media from HEK293 cells stably expressing soluble FGFR2c-His

www.daresburyproteins.co.uk

Available in Canada from...

MJS
BioLynx
INC.

1-888-593-5969 • www.biolynx.ca • tech@biolynx.ca



Proteins for cutting edge research, recombinant FGFR3b and FGFR3c


FGFR3b and FGFR3c are both alternatively spliced isoforms representing epithelial and mesenchymal variants of FGFR3. Daresbury Proteins come highly recommended. On the advice of an academic collaborator, these proteins were successfully utilized by a large global pharma company for internal R&D on the mechanism of action of one of their top-selling therapeutics.

Produce ground-breaking data, recombinant FGFR4

FGFR4 is also known as CD334 and has been shown to bind to FGF1. Recombinant Human Fibroblast Growth Factor Receptor 4 was expressed in HEK293 cells and is supplied in liquid format.

For trial samples of the FGFR proteins produced by Daresbury Proteins, and for more information on their range of unique recombinant human proteins for research, clinical and diagnostic applications, visit:

<https://www.daresburyproteins.co.uk/>




FGFR3b - Grade & Purity: >95% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).

References:

(1) Chae, Y. K. et al. *Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.* Oncotarget vol. 8,9 (2017): 16052-16074.

(2) Porta, R. et al. *FGFR a promising druggable target in cancer: Molecular biology and new drugs.* Crit Rev Oncol Hematol. vol. 113 (2017): 256-267.



Validation:

Western blot analysis of conditioned media from non-transfected HEK293 cells, FGFR2b-His and FGFR2c-His transfected HEK293 cells.

Lane 1: Conditioned media from non-transfected HEK293 cells

Lane 2: Conditioned media from HEK293 cells stably expressing soluble FGFR2b-His

Lane 3: Conditioned media from HEK293 cells stably expressing soluble FGFR2c-His

www.daresburyproteins.co.uk